GlassScriptPhysician profile
David S Roby
NPI 1215926175
$26,249.51
in general payments reported to CMS, 2019-2025
28 companies · $848 in 2025
The $848 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $9,367 · 2021: $12K · 2022: $1,789 · 2023: $519 · 2024: $315 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,573 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,572.74 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,425.54 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Allergan, INC. | $10,872.89 | 2020-2021 | |
| Lilly USA, LLC | $532.42 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Ucb, INC. | $477.77 | 2019-2024 | Briviact |
| Pfizer INC. | $368.62 | 2023-2025 | |
| Amgen INC. | $345.57 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $267.70 | 2019-2025 | Austedo Xr |
| Amneal Pharmaceuticals LLC | $93.81 | 2019-2022 | |
| Eisai INC. | $87.99 | 2019-2022 | |
| Genentech USA, INC. | $83.44 | 2024-2025 | Ocrevus Zunovo |
| Biohaven Pharmaceuticals, INC. | $79.28 | 2021 | |
| Novartis Pharmaceuticals Corporation | $71.39 | 2019-2021 | |
| Biogen, INC. | $70.32 | 2021 | |
| Sumitomo Pharma America, INC. | $65.28 | 2023 | Aptiom |
| Alexion Pharmaceuticals, INC. | $51.47 | 2023-2024 | Soliris |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $50.44 | 2022 | |
| Avanir Pharmaceuticals, INC. | $43.69 | 2019 | |
| Emd Serono, INC. | $38.50 | 2019 | |
| Sunovion Pharmaceuticals INC. | $38.04 | 2019 | |
| Sk Life Science, INC. | $29.85 | 2022 | |
| Acorda Therapeutics, INC | $24.98 | 2019 | |
| Mallinckrodt Enterprises LLC | $22.71 | 2019 | |
| Merz Pharmaceuticals, LLC | $22.37 | 2024 | Xeomin |
| Boston Scientific Corporation | $20.00 | 2021 | |
| Mallinckrodt Hospital Products INC. | $17.43 | 2020 | |
| Kyowa Kirin, INC. | $17.18 | 2020 | |
| Lundbeck LLC | $17.14 | 2022 | |
| Neurelis, INC. | $13.69 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Roby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.